Sensex
84,686.15 profit arw 123.37 (0.15%)
Nifty
25,939.55 profit arw 29.50 (0.11%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 14-Nov-2025
Corporate News
14-Nov-2025     18:49

Zydus receives USFDA approval for Leuprolide Acetate injection

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection', 1 mg/0.2 mL).

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer.

Leuprolide Acetate injections will be manufactured at the Company's oncology injectable manufacturing facility at SEZ1, Ahmedabad ('ALIDAC').

Leuprolide Acetate injection had annual sales of USD 69 mn in the United States (IQVIA MAT Sept 2025).

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

84,686.15 123.37 (0.15%)

Nifty

25,939.55 29.50 (0.11%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

26,572.47 -500.56(-1.85%)